Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services. It operates through the following two segments: Generic and Specialty Medicine. The Generic segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment includes several franchises, most significantly core therapeutic areas of CNS medicines. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
Market Cap | 9.342 Billion | Shares Outstanding | 1.103 Billion | Avg 30-day Volume | 9.864 Million |
P/E Ratio | 21.1873 | Dividend Yield | 0.0 | EPS | 0.19 |
Price to Revenue | 0.5564 | Debt to Equity | 2.0494 | EBITDA | 1.988 Billion |
Price to Book Value | 0.8596 | Operating Margin | 10.807400000000001 | Enterprise Value | 30.679 Billion |
Current Ratio | 1.14 | EPS Growth | 1.104 | Quick Ratio | 0.607 |
1 Yr BETA | 0.936 | 52-week High/Low | 11.55 / 7.23 | Profit Margin | 2.8719 |
Operating Cash Flow Growth | -34.375 | Altman Z-Score | 0.2539 | Free Cash Flow to Firm | 3.677 Billion |
Please sign in first
none
130 Thousand total shares from 1 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
FRIDRIKSDOTTIR HAFRUN EXECUTIVE VP, GLOBAL R&D |
|
1,387 | 2022-05-17 | 5 |
SABAG MARK EVP, INTERNATIONAL MARKETS |
|
552,788 | 2022-03-04 | 3 |
STARK DAVID MATTHEW EXEC. VP CHIEF LEGAL OFFICER |
|
383,202 | 2022-03-04 | 3 |
SCHULTZ KARE PRESIDENT AND CEO |
|
3,456,597 | 2022-03-04 | 4 |
DETHLEFS SVEN EVP, NORTH AMERICA COMMERCIAL |
|
728,120 | 2022-03-04 | 3 |
DANIELL RICHARD EXEC. VP, EUROPEAN COMMERCIAL |
|
369,819 | 2022-03-04 | 3 |
DRAPE ERIC EXECUTIVE VP GLOBAL OPERATIONS |
|
448,024 | 2022-03-04 | 3 |
KALIF ELIYAHU SHARON EVP, CHIEF FINANCIAL OFFICER |
|
263,088 | 2022-03-04 | 3 |
SHANI ELI EVP,GLOBAL MARKETING&PORTFOLIO |
|
131,715 | 2022-03-04 | 3 |
INBAR GALIA SEE "REMARKS" |
|
112,926 | 2022-03-04 | 3 |
WEISS AMIR CHIEF ACCOUNTING OFFICER |
|
101,360 | 2022-03-04 | 3 |
|
17 | 2021-12-31 | 3 | |
WEIL ANDREW CHIEF ACCOUNTING OFFICER |
|
29,673 | 2021-11-02 | 1 |
|
14,479 | 2021-06-14 | 3 | |
|
25,791 | 2021-06-14 | 3 | |
|
14,479 | 2021-06-14 | 3 | |
|
14,479 | 2021-06-14 | 3 | |
|
14,479 | 2021-06-14 | 2 | |
|
14,479 | 2021-06-14 | 3 | |
|
14,479 | 2021-06-14 | 3 | |
|
14,479 | 2021-06-14 | 3 | |
|
14,479 | 2021-06-14 | 3 | |
|
51,359 | 2021-06-14 | 3 | |
|
14,479 | 2021-06-14 | 1 | |
NAZZI GIANFRANCO EVP, INTERNATIONAL MARKETS |
|
25,870 | 2021-03-04 | 0 |
O'GRADY BRENDAN P. EVP, NORTH AMERICA COMMERCIAL |
|
188,299 | 2021-03-04 | 0 |
GRIFFIN DEBORAH A CHIEF ACCOUNTING OFFICER |
|
0 | 2020-03-17 | 0 |
MCCLELLAN MICHAEL JAMES EVP, CHIEF FINANCIAL OFFICER |
|
15,898 | 2019-11-05 | 0 |
|
0 | 2019-06-11 | 0 | |
DE NOTARISTEFANI CARLO EXECUTIVE VP GLOBAL OPERATIONS |
|
33,589 | 2019-05-18 | 0 |
CODNER IRIS BECK EVP GLOBAL BRAND&COMMUNICATION |
|
0 | 2019-03-04 | 0 |
|
318,836 | 2018-01-19 | 0 | |
|
0 | 2018-01-01 | 0 | |
|
0 | 2018-01-01 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-19 07:31:18 -0400 | 2022-05-17 | S | 130,000 | $8.22 | d | 1,387 | direct | 1.9254 | 1.9254 | 2 | 0.0 | 1 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 22:15:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 21:45:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 21:15:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 20:45:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 20:15:05 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 19:45:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 19:15:04 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 18:45:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 18:15:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 17:45:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 17:15:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 16:45:04 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 16:15:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 15:45:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 15:15:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 14:45:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 14:15:04 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 13:45:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 13:15:03 UTC | 0.4119 | 0.4081 | 0 |
TEVA PHARMACEUTICAL-SP ADR TEVA | 2022-05-20 12:45:03 UTC | 0.4119 | 0.4081 | 0 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
UBS RELATIONSHIP FUNDS- UBS U.S. EQUITY ALPHA RELATIONSHIP FUND | TEVA | -145400.0 shares, $-1792782.0 | 2020-06-30 | N-PORT |
INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund | TEVA | -14705.0 shares, $-169695.7 | 2021-03-31 | N-PORT |
Legg Mason Global Asset Management Trust- Franklin Global Market Neutral Fund | TEVA | -46800.0 shares, $-439452.0 | 2022-03-31 | N-PORT |